Cartesian Therapeutics, Inc. · NASDAQ:RNAC
Cartesian Therapeutics — 2026 MGFA Scientific Session at AANEM
14 slides from Cartesian Therapeutics's conference presentation, Sep 29, 2026
Slide 1: Durability of response following retreatment with Descartes-08 in generalized myasthenia gravis
Durability of response following retreatment with Descartes-08, an autologous BCMA-directed mRNA CAR T-cell therapy, in generalized myasthenia gravis: a case series with 12-month follow-up James F. Howard Jr.1, Mamatha Pasnoor2, Nizar Chahin3, Hafsa Kamboh4, Eva Rybak4, Renee Fedak4, Milos Miljkovic
Slide 2: Disclosures
Disclosures Commercial interest Relationship(s) Ad Scientiam, Alexion AstraZeneca Rare Disease, argenx, Cartesian Therapeutics, Centers for Disease Control and Prevention, Merck EMD Serono, Myasthenia Gravis Foundation of America (MGFA), Muscular Dystrophy Association, Grants/research support Nati
Slide 3: Cells involved in myasthenia gravis pathogenesis express BCMA
Cells involved in myasthenia gravis pathogenesis express BCMA • In anti-AChR–positive MG, pathogenic autoantibodies are produced by BCMA-expressing long- lived plasma cells.1-4 • BCMA-directed cell therapy targets BCMA-expressing antibody- producing cells, addressing a key driver of MG pathology.5-7
Slide 4: Cartesian mRNA cell therapy platform
Cartesian mRNA cell therapy platform WHAT IS DESCARTES-08 Descartes-08 is an investigational autologous, nonviral, BCMA-targeted, mRNA CAR T-cell product candidate designed to be dosed in an outpatient setting without lymphodepleting chemotherapy 4 Descartes-08 is an investigational product candidat
Slide 5: mRNA cell therapy designed for outpatient delivery
mRNA cell therapy designed for outpatient delivery The patient’s T cells are isolated, expanded ex vivo, and engineered to become BCMA-directed CAR T cells1,2 so the therapeutic dose does not rely on in vivo proliferation. 1 2 3 4 5 6 7 Cell collection/ Cell Selection1 Ex-vivo T-cell Transfection1 C
Slide 6: MG-001 Clinical Program Summary
MG-001 Clinical Program Summary 3-Part Phase 1b/2 study of Descartes-08 in MG (NCT04146051) Across the MG-001 program, Descartes-08 demonstrated clinically meaningful and sustained improvements in MG clinical outcome measures1-3 Inpatient Outpatient • In Phase 2a, clinical effect was PART 1: Phase 1
Slide 7: Retreatment case series
Retreatment case series MG-001 participants previously treated with Descartes-08 • The case series analyzed the efficacy, safety, and Phase 2a durability of response to Descartes-08 retreatment in (n=3) participants with gMG who previously received a full treatment course in the Phase 2 portion of t
Slide 8: Retreatment case series: Participant baseline characteristics
Retreatment case series: Participant baseline characteristics Characteristic Participants (n=5) Age, mean (SD) 58 (12) years Age range 49–79 Women, n (%) 4 (80%) AChR+ gMG, n (%) 4 (80%) MG-ADL at baseline before initial treatment, 9.2 (3.1) mean (SD) MG-ADL at baseline before retreatment, 9.6
Slide 9: Descartes-08 improvement in mean change from baseline in MGC
Results: Descartes-08 demonstrated improvement in mean change from baseline in MGC following initial treatment and retreatment Initial Treatment Retreatment Mean Change from Baseline in MGC Score Mean Change from Baseline in MGC Score 5 5 0 0 *Clinically meaningful decrease *Clinically meaningful de
Slide 10: Descartes-08 improvement in mean change from baseline in MG-ADL
Results: Descartes-08 demonstrated improvement in mean change from baseline in MG-ADL following initial treatment and retreatment Initial Treatment Retreatment Mean Change from Baseline in ADL Score Mean Change from Baseline in ADL Score 5 5 0 *Clinically meaningful decrease *Clinically meaningful d
Slide 11: Safety Summary
Safety Summary Retreatment safety profile was consistent with initial treatment, with no new or cumulative safety signals observed Initial Treatment vs Retreatment (n=5) 6 once-weekly infusions per treatment course Safety Event Initial Treatment Retreatment SAEs# 1 0 Infusion-related reaction (IRR)*
Slide 12: Case #1 (Phase 2a)
Case #1 (Phase 2a) MG History: 52-year-old Caucasian Woman Initial Treatment Retreatment • 16-year history of AChR+ gMG, MGFA Class IIa at screening 15 • Prior therapies include prednisone, pyridostigmine, eculizumab, MMF, PLEX, IVIG, thymectomy • Disease course has been complicated by MC requiring
Slide 13: Case #2 (Phase 2a)
Case #2 (Phase 2a) MG History: 67-year-old Caucasian Man Initial Treatment Retreatment 8 • 10-year history of seronegative gMG, MGFA Class IIa at screening • Prior therapies include IVIG, PLEX, MMF, prednisone, 6 azathioprine, MTX • Receiving prednisone and pyridostigmine at time of initial treatmen
Slide 14: Conclusion
Conclusion Among participants with gMG who initially responded to Descartes-08 and later experienced recurrence of symptoms (MG-ADL ≥6), retreatment with Descartes-08 led to improvements in MG severity scores Clinical benefit following retreatment was sustained through Month 12 in multiple participa
Cartesian Therapeutics — 2026 MGFA Scientific Session at AANEM on 6ix